Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2013-09-18 M&A Activity
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
M&A Activity 2013
M&A Activity Classification · 99% confidence The document text is very short (506 characters) and written in Danish. It announces the signing of a collaboration agreement between Novozymes and Raízen Energia S/A regarding enzyme technology for cellulosic ethanol production. Crucially, the last line states, 'Læs hele meddelelsen i pdf format' (Read the entire announcement in pdf format). According to Rule #2 (The 'Menu vs Meal' Rule), a short announcement whose primary purpose is to state that a full document/announcement is available elsewhere (like in a PDF) should be classified as a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since this is a specific business development announcement (collaboration agreement), it doesn't fit perfectly into the defined categories like M&A (TAR) or Financing (CAP). Given the nature of announcing a specific business event and directing the user to the full document, RPA is the most appropriate classification, as it signals the publication of a more detailed announcement.
2013-09-18 Danish
Regulatory Filings 2013
Regulatory Filings Classification · 95% confidence The document is a short announcement dated September 18, 2013, detailing a new strategic collaboration between Novozymes and Raízen regarding cellulose-based ethanol production. It provides key business updates, quotes management, and includes contact information. Crucially, it ends with 'Selskabsmeddelelse nr. 22, 2013 Side 1 af 1' (Company Announcement no. 22, 2013 Page 1 of 1). This structure strongly suggests a formal, brief regulatory disclosure or press release announcing a significant business event that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a general regulatory announcement that doesn't fit M&A (TAR), Capital (CAP), or Director Dealing (DIRS), the most appropriate general category is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it explicitly states no effect on 2013 financial expectations, nor is it a full report (10-K, IR).
2013-09-18 English
Earnings Release 2013
Earnings Release Classification · 100% confidence The document provides a summary of financial results for the first half of the year ('1. halvår 2013'), detailing organic sales growth, margin changes, operating profit, and outlook adjustments for the full year. It includes commentary from the CEO regarding performance against expectations. This content structure—a concise summary of period results with forward-looking guidance—is characteristic of an Earnings Release (ER). Although it mentions reading the full announcement in PDF format, the provided text itself is the core release content, not just an announcement about the release (which would be RPA/RNS). Since it focuses on period results rather than comprehensive annual data (10-K) or a detailed management discussion (MDA), ER is the most appropriate classification. H1 2013
2013-08-09 Danish
Earnings Release 2013
Earnings Release Classification · 100% confidence The document provides key financial highlights for the first half of 2013, including organic sales growth (6%), EBIT margin (24.6%), and maintained full-year outlook adjustments regarding DKK sales growth, EBIT growth, and net profit growth. This content structure—summarizing period performance and providing forward guidance—is characteristic of an Earnings Release (ER). The document is short (1622 chars) and ends with a prompt to 'Read the full announcement in PDF format,' which suggests it is the initial press release announcing the results, not the comprehensive report itself. Therefore, ER is the most appropriate classification. H1 2013
2013-08-09 English
Board/Management Information 2013
Board/Management Information Classification · 99% confidence The document text describes a change in Novozymes' internal structure specifically related to how its sales areas are defined and reported to the financial markets. It details the reorganization of segments like BioBusiness, Microorganisms, and Biopharma into new reporting areas (Household Care, Food & Beverages, Bioenergy, Agriculture & Feed, Technical & Pharma) and provides the percentage contribution of these new areas based on 2012 sales. This content relates to how the company structures and communicates its operational segments, which falls under management or operational reporting structure changes. Since there is no specific category for 'Sales Structure Change', the closest fit is 'Management Information' (MANG) as it details changes in how the business is organized and reported, or potentially 'Regulatory Filings' (RNS) if it's a mandatory disclosure of structural changes. Given the focus on internal structure alignment for market communication, MANG is the most appropriate classification, although it is not a change in Board/Management personnel. However, the document is very short (1382 chars) and ends with 'Read the full announcement in PDF format,' suggesting it might be an announcement *about* a filing rather than the full filing itself. If it were a full MDA, it would be much longer. Since it announces a structural change impacting reporting, and MANG covers management/board changes, I will check other options. It is not an ER, IR, or 10-K. It is not a DIV, CAP, or DIRS. Given the nature of reporting structure changes, and lacking a specific 'Operational Structure Change' code, I will classify it as a general announcement related to business structure, which often falls under Management/Board updates (MANG) or the general Regulatory Filings (RNS). Because it details specific operational segment changes for reporting purposes, MANG is slightly more descriptive than RNS. I will assign a high confidence score based on the clear content describing structural reporting changes.
2013-06-17 English
Management Reports 2013
Management Reports Classification · 95% confidence The document is dated June 17, 2013, and is titled 'Selskabsmeddelelse nr. 20, 2013' (Company Announcement No. 20, 2013). The content explicitly states that Novozymes is changing its sales areas ('ændres salgsområderne') for reporting to the financial markets and provides detailed tables showing the historical sales distribution (2008-2013) under the new structure. This is an announcement regarding a change in internal structure and how financial data will be segmented and reported going forward. It is not a full annual report (10-K), an interim report (IR), or a standard earnings release (ER) which typically focuses on period performance. Since it is an official announcement detailing changes relevant to financial reporting and structure, and it is not a standard regulatory form like 10-K or IR, it fits best under a general corporate announcement category. Given the context of restructuring financial reporting segments, it is a significant corporate update. It is not a proxy statement (DEF 14A), dividend notice (DIV), or management discussion (MDA). Since it is a formal announcement about changes impacting financial reporting structure, and it is not explicitly covered by other specific codes like MANG or CAP, it falls under the general regulatory/corporate announcement category, RNS, or potentially a specific type of corporate governance/reporting change. However, since the core action is announcing a change in reporting structure and providing updated historical data tables, and it is a formal 'Selskabsmeddelelse' (Company Announcement), RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it strongly relates to financial reporting structure. Given the detailed financial tables provided, it is more than just a brief notice. If a specific code for 'Reporting Structure Change' existed, that would be ideal. Lacking that, RNS is the best fit for a formal, non-standard announcement. Revisiting the definitions: It is an announcement about how future financial data will be presented, including historical restatements. This is a significant corporate action impacting investor analysis. It is not a standard ER, IR, or 10-K. It is a formal announcement ('Selskabsmeddelelse'). This type of announcement, detailing changes to segment reporting, is often classified under general regulatory filings (RNS) when a more specific code isn't available. I will classify it as RNS.
2013-06-17 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.